Adipocyte microRNA-802 promotes adipose tissue inflammation and insulin resistance by modulating macrophages in obesity
eLife · 2024
DOI: 10.7554/elife.99162 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Yue Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, School of life Science and Technology, China…. Hauptthemen laut MEDLINE: MicroRNAs, Insulin Resistance, Macrophages, Obesity. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Jiangsu Province Outstanding Postdoctoral Program.
Abstract (Originalsprache)
Adipose tissue inflammation is now considered to be a key process underlying metabolic diseases in obese individuals. However, it remains unclear how adipose inflammation is initiated and maintained or the mechanism by which inflammation develops. We found that microRNA-802 ( Mir802 ) expression in adipose tissue is progressively increased with the development of dietary obesity in obese mice and humans. The increasing trend of Mir802 preceded the accumulation of macrophages. Adipose tissue-specific knockout of Mir802 lowered macrophage infiltration and ameliorated systemic insulin resistance. Conversely, the specific overexpression of Mir802 in adipose tissue aggravated adipose inflammation in mice fed a high-fat diet. Mechanistically, Mir802 activates noncanonical and canonical NF-κB pathways by targeting its negative regulator, TRAF3. Next, NF-κB orchestrated the expression of chemokines and SREBP1, leading to strong recruitment and M1-like polarization of macrophages. Our findings indicate that Mir802 endows adipose tissue with the ability to recruit and polarize macrophages, which underscores Mir802 as an innovative and attractive candidate for miRNA-based immune therapy for adipose inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, School of life Science and Technology, China Pharmaceutical University, Nanjing, China.
- NanJing HanKai Academy, Nanjing, China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
- Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
ORCID-Profile: Liang Jin, Fangfang Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Jiangsu Province Outstanding Postdoctoral Program
- Jiangsu Province Research Founding for Postdoctoral
- '111' project
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Yang, Y., Huang, B., Qin, Y., Wang, D., Jin, Y., Su, L., Wang, Q., Pan, Y., Zhang, Y., Shen, Y., Hu, W., Cao, Z., Jin, L., & Zhang, F. (2024). Adipocyte microRNA-802 promotes adipose tissue inflammation and insulin resistance by modulating macrophages in obesity. eLife. https://doi.org/10.7554/elife.99162
Vancouver
Yang Y, Huang B, Qin Y, Wang D, Jin Y, Su L, et al. Adipocyte microRNA-802 promotes adipose tissue inflammation and insulin resistance by modulating macrophages in obesity. eLife. 2024. doi:10.7554/elife.99162
BibTeX
@article{Yang2024,
author = {Yang, Yue and Huang, Bin and Qin, Yimeng and Wang, Danwei and Jin, Yinuo and Su, Linmin and Wang, Qingxin and Pan, Yi and Zhang, Yanfeng and Shen, Yumeng and Hu, Wenjun and Cao, Zhengyu and Jin, Liang and Zhang, Fangfang},
title = {Adipocyte microRNA-802 promotes adipose tissue inflammation and insulin resistance by modulating macrophages in obesity},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.99162}
}
EUVIMED